Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07049926 · ClinicalTrials.gov registry record · Phase 1
Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
A Phase 1 study of Renal Cell Carcinoma, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 140
- Enrollment target
- 20
- Study locations
NCT07049926 is a Phase 1 study of Renal Cell Carcinoma that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 140 participants, below the 242-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (42% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT07049926, a Phase 1 study of Renal Cell Carcinoma, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 140 participants
- Enrollment target
- 20
- Study locations
Study Summary
Substudy 03C is part of a larger research study that is testing experimental treatments for renal cell carcinoma (RCC). The larger study is the umbrella study (U03). The goal of substudy 03C is to evaluate the safety and efficacy of experimental combinations of investigational agents in participants with clear cell renal cell carcinoma (ccRCC) who have recurrent disease during or after anti-programmed cell death 1/programmed cell death ligand 1 (PD-\[L\]1) adjuvant therapy. This substudy will have two phases: a safety lead-in phase and an efficacy phase. The safety lead-in phase will be used to demonstrate a tolerable safety profile for the combination of investigational agents. There will be no hypothesis testing in this study
Conditions Studied
Interventions
- DRUG Belzutifan
- DRUG Zanzalintinib
Study Locations (20)
Other
- Rambam Health Care Campus ( Site 5500) - Haifa
- Rabin Medical Center ( Site 5502) - Petah Tikva
- Sheba Medical Center ( Site 5501) - Ramat Gan
- Sourasky Medical Center ( Site 5503) - Tel Aviv
- Severance Hospital ( Site 5802) - Seoul
New York
- Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 5026) - Mineola
- Laura and Isaac Perlmutter Cancer Center ( Site 5016) - New York
- Memorial Sloan Kettering Cancer Center ( Site 5002) - New York
Region M. de Santiago
- Centro de Estudios Clínicos SAGA ( Site 6110) - Santiago
- Bradfordhill ( Site 6101) - Santiago
California
- UCSF Medical Center at Mission Bay ( Site 5008) - San Francisco
North Carolina
- Duke Cancer Institute ( Site 5015) - Durham
Pennsylvania
- UPMC Cancer Center/Hillman Cancer Center ( Site 5017) - Pittsburgh
Bas-Rhin
- C.H.U. de Strasbourg Hopital de Hautepierre ( Site 5203) - Strasbourg
Haute-Garonne
- Institut Claudius Regaud ( Site 5200) - Toulouse
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2025-07-20 |
| Est. Completion | 2031-10-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07049926
The ClinicalTrials.gov registry entry for NCT07049926 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 242-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (42% lower). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Belzutifan is the first listed.
NCT07049926 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Other, New York, Region M. de Santiago.
Frequently Asked Questions
What is clinical trial NCT07049926 about?
NCT07049926 is a clinical study titled "Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)". Substudy 03C is part of a larger research study that is testing experimental treatments for renal cell carcinoma (RCC). The larger study is the umbrella study (U03). The goal of substudy 03C is to evaluate the safety and efficacy of experimental combinations of investigational agents in participant...
What is the current status of trial NCT07049926?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 140 participants. The study started on 2025-07-20. Estimated completion is 2031-10-26.
What conditions does trial NCT07049926 study?
This clinical trial studies the following conditions: Renal Cell Carcinoma.
What interventions are being tested in trial NCT07049926?
The interventions under investigation include: Belzutifan (DRUG), Zanzalintinib (DRUG).
Who is sponsoring clinical trial NCT07049926?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07049926 being conducted?
This trial has 20 study locations across California, New York, North Carolina, Pennsylvania, Region M. de Santiago. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
RECRUITING · Phase 1
-
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
RECRUITING · Phase 1
-
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
RECRUITING · Phase 1
-
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.